## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.1% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($46.82)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $57 From $51, Maintains Neutral Rating**
- Source: MarketScreener | 20251201T115200 | Somewhat-Bullish | Relevance: 99%
- Goldman Sachs has adjusted its price target for Bristol-Myers Squibb to $57, up from $51, while maintaining a Neutral rating on the stock. This update reflects Goldman Sachs' ongoing assessment of the pharmaceutical company's financial outlook and market position. The article also provides a company profile and recent news related to Bristol-Myers Squibb, including other analyst rating changes and regulatory approvals.

**2. BMY Gains Attention as Bayer Reports FXIa Trial Success**
- Source: Insider Monkey | 20251130T142700 | Neutral | Relevance: 99%
- Bristol-Myers Squibb (NYSE: BMY) is gaining attention after Bayer reported positive Phase 3 results for its FXIa inhibitor, asundexian, potentially increasing interest in similar treatments. While BMY is not experiencing significant growth, it remains profitable with a sustainable payout ratio of around 84% and strong free cash flow generation. However, concerns about its $32 billion net debt could impact future dividend safety despite a recent reduction.

**3. Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus**
- Source: ts2.tech | 20251130T003632 | Neutral | Relevance: 99%
- This article examines Bristol-Myers Squibb (BMY) stock as of November 29, 2025, highlighting its 5.4% dividend yield, significant institutional buying, and a general "Hold" consensus from Wall Street analysts. It delves into the company's performance, valuation, dividend debate amidst patent cliffs and regulatory pressures, and recent strategic moves, while also outlining key risks and what the news means for investors.

**4. Pre-tax profits at Bristol Myers Squibb down 47%**
- Source: RTE.ie | 20251201T162800 | Neutral | Relevance: 99%
- Pre-tax profits at Bristol Myers Squibb's main Irish unit, Swords Laboratories UC, declined by 47% to $2.09 billion in 2024, despite a 21% reduction in revenues to $12.27 billion. This revenue figure represents 25.4% of Bristol Myers Squibb's global revenues. The company attributes the decrease to changes in product mix, pricing, volume, and the timing of new product manufacturing and distribution.

**5. Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules**
- Source: Reuters | 20251201T214900 | Neutral | Relevance: 98%
- A U.S. judge has ruled that Bristol Myers Squibb (BMY.N) must face a $6.7 billion lawsuit. The lawsuit alleges the company cheated former Celgene shareholders by delaying federal approval for three drugs, including the cancer treatment Breyanzi. While some claims were dismissed, the plaintiff UMB Bank can pursue breach of contract claims on behalf of shareholders.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |
| 2025-12-02 | Goldman Sachs | $57 | $51 | +12% |
| 2025-11-17 | Citigroup | $45 | $48 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Scotiabank | main | Sector Perform |
| 2025-12-02 | Goldman Sachs | main | Neutral |
| 2025-11-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $104.3B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.2 |
| Current P/E | 7.5 |
| YoY Growth | -8.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.5% over 5 days). Below STRENGTH zone by 1.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Below SMA200 (1.00x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.08% (CS: 72) | Neutral |
| RSI_14 | 64.7 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.038x | Above |
| vs SMA50 | 1.079x | Above |
| vs SMA200 | 1.000x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $49.18
- **Stop Loss:** $46.82 (4.8% risk)
- **Target:** $51.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 317
- **Position Value:** $15,590.06
- **Portfolio %:** 15.59%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*